369 related articles for article (PubMed ID: 23294275)
1. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Roth A; Becka M; Alatrach A; Halabi A; Hinrichsen H; Mueck W
Br J Clin Pharmacol; 2013 Jul; 76(1):89-98. PubMed ID: 23294275
[TBL] [Abstract][Full Text] [Related]
2. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Mueck W; Halabi A; Maatouk H; Klause N; Lufft V; Wand DD; Philipp T; Bruck H
Br J Clin Pharmacol; 2010 Nov; 70(5):703-12. PubMed ID: 21039764
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
[TBL] [Abstract][Full Text] [Related]
4. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.
Kubitza D; Becka M; Zuehlsdorf M; Mueck W
J Clin Pharmacol; 2007 Feb; 47(2):218-26. PubMed ID: 17244773
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
Graff J; Harder S
Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
[TBL] [Abstract][Full Text] [Related]
6. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor.
Kubitza D; Becka M; Roth A; Mueck W
J Clin Pharmacol; 2013 Mar; 53(3):249-55. PubMed ID: 23381840
[TBL] [Abstract][Full Text] [Related]
7. Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban.
Moore KT; Plotnikov AN; Thyssen A; Vaccaro N; Ariyawansa J; Burton PB
J Cardiovasc Pharmacol; 2011 Dec; 58(6):581-8. PubMed ID: 21822144
[TBL] [Abstract][Full Text] [Related]
8. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects.
Kubitza D; Becka M; Roth A; Mueck W
Curr Med Res Opin; 2008 Oct; 24(10):2757-65. PubMed ID: 18715524
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics and pharmacodynamics of single doses of rivaroxaban - an oral, direct factor Xa inhibitor - in elderly Chinese subjects.
Jiang J; Hu Y; Zhang J; Yang J; Mueck W; Kubitza D; Bauer RJ; Meng L; Hu P
Thromb Haemost; 2010 Jan; 103(1):234-41. PubMed ID: 20062915
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban.
Mueck W; Stampfuss J; Kubitza D; Becka M
Clin Pharmacokinet; 2014 Jan; 53(1):1-16. PubMed ID: 23999929
[TBL] [Abstract][Full Text] [Related]
12. The effect of food on the absorption and pharmacokinetics of rivaroxaban.
Stampfuss J; Kubitza D; Becka M; Mueck W
Int J Clin Pharmacol Ther; 2013 Jul; 51(7):549-61. PubMed ID: 23458226
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes.
Xu XS; Moore K; Burton P; Stuyckens K; Mueck W; Rossenu S; Plotnikov A; Gibson M; Vermeulen A
Br J Clin Pharmacol; 2012 Jul; 74(1):86-97. PubMed ID: 22242932
[TBL] [Abstract][Full Text] [Related]
14. An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function.
Moore KT; Vaidyanathan S; Natarajan J; Ariyawansa J; Haskell L; Turner KC
J Clin Pharmacol; 2014 Dec; 54(12):1407-20. PubMed ID: 24964176
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects.
Kubitza D; Becka M; Wensing G; Voith B; Zuehlsdorf M
Eur J Clin Pharmacol; 2005 Dec; 61(12):873-80. PubMed ID: 16328318
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.
Mueck W; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Kälebo P; Muelhofer E; Misselwitz F; Eriksson BI
Thromb Haemost; 2008 Sep; 100(3):453-61. PubMed ID: 18766262
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects.
Kubitza D; Becka M; Mück W; Krätzschmar J
Br J Clin Pharmacol; 2014 Aug; 78(2):353-63. PubMed ID: 24528331
[TBL] [Abstract][Full Text] [Related]
18. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor xa inhibitor--in healthy subjects.
Mueck W; Becka M; Kubitza D; Voith B; Zuehlsdorf M
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):335-44. PubMed ID: 17595891
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz R
Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
[TBL] [Abstract][Full Text] [Related]
20. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects.
Zhao X; Sun P; Zhou Y; Liu Y; Zhang H; Mueck W; Kubitza D; Bauer RJ; Zhang H; Cui Y
Br J Clin Pharmacol; 2009 Jul; 68(1):77-88. PubMed ID: 19660005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
